Masha Resman, MD
Internal Medicine · Houston, TXNPI 1013143890
Payments from drug & device makers
Across 381 payments — averaging $24.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Corcept Therapeutics$3K
- Amgen$1K
- Novo Nordisk$649
- AbbVie$515
- Lilly USA, LLC$498
- Radius Health, Inc.$457
- plus $4K from 33 others
What the payments were for
- Speaking & faculty fees$1,82019%
- Food & beverage$7,53180%
- Education$701%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Corcept Therapeutics | 29 | $2,575 |
| Amgen(2 entities) | 65 | $1,215 |
| Novo Nordisk | 38 | $649 |
| AbbVie | 27 | $515 |
| Lilly USA, LLC | 30 | $498 |
| Radius Health, Inc. | 23 | $457 |
| Abbott | 21 | $407 |
| Dexcom, Inc. | 11 | $333 |
| Tandem Diabetes Care, Inc. | 14 | $304 |
| Sanofi-aventis U.S. LLC | 16 | $298 |
| Merck | 17 | $266 |
| Insulet Corporation | 10 | $229 |
| Madrigal Pharmaceuticals | 5 | $218 |
| IBSA Pharma Inc. | 10 | $181 |
| Xeris Pharmaceuticals, Inc. | 9 | $158 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $149 |
| AstraZeneca | 8 | $130 |
| Bayer | 7 | $120 |
| Amneal Pharmaceuticals LLC | 5 | $97 |
| Mannkind Corporation | 3 | $85 |
| Boehringer Ingelheim | 4 | $73 |
| Alvogen Inc | 3 | $68 |
| Medtronic | 1 | $50 |
| Cequr Corporation | 2 | $44 |
| Neurocrine Biosciences, Inc. | 1 | $32 |
| Recordati_rare_diseases_inc. | 1 | $28 |
| Genentech USA, Inc. | 1 | $26 |
| Novartis | 1 | $24 |
| Amryt Pharma Holdings Ltd | 1 | $22 |
| Astellas Pharma US Inc | 1 | $22 |
| Halozyme Inc | 1 | $21 |
| Amarin Pharma, Inc. | 1 | $19 |
| Sequel Med Tech, LLC | 1 | $18 |
| Ironwood Pharmaceuticals, Inc | 1 | $18 |
| GSK | 1 | $17 |
| Tolmar, Inc. | 1 | $15 |
| Averitas Pharma Inc. | 1 | $14 |
| Companion Medical, Inc. | 1 | $14 |
| Currax Pharmaceuticals LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Korlym$1,938
- REZDIFFRA$136
- DEXCOM CGM$123
- EVENITY$103
- TEPEZZA$102
How this compares
$9,421 in reported general payments places this provider in the 90th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 256 | $395,202 |
| JardianceEmpagliflozin | 211 | $310,381 |
| MounjaroTirzepatide | 151 | $235,451 |
| TrulicityDulaglutide | 79 | $169,004 |
| Tresiba Flextouch U-100Insulin Degludec | 109 | $109,057 |
| FarxigaDapagliflozin Propanediol | 98 | $104,991 |
| ForteoTeriparatide | 18 | $80,646 |
| Teriparatide | 19 | $60,285 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 38 | $56,925 |
| ProliaDenosumab | 33 | $56,235 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 47 | $53,045 |
| Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt | 33 | $51,872 |
| JanuviaSitagliptin Phosphate | 35 | $49,554 |
| Tresiba Flextouch U-200Insulin Degludec | 32 | $39,739 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 17 | $33,310 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Forteo, Humalog, Insulin Lispro | $498 | $501,665318 claims |
| Novo NordiskOzempic, Novolog | $649 | $404,081280 claims |
| Boehringer IngelheimJardiance, Tradjenta | $73 | $327,630235 claims |
| AstraZenecaFarxiga | $130 | $104,99198 claims |
| MerckJanuvia, Janumet Xr | $266 | $62,97950 claims |
| Alvogen IncTeriparatide | $68 | $60,28519 claims |
| AmgenProlia | $1,215 | $56,23533 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $298 | $37,70339 claims |
| AbbVieSynthroid | $515 | $12,539117 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid | $97 | $8,275450 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCCycloset | $149 | $3,86813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in Houston
- Jan BurgerHouston$47.3M
- Nitin JainHouston$33.2M
- Aung NaingHouston$30.6M
- Preetesh JainHouston$19.5M
- Paolo StratiHouston$19.2M
- Nicholas ShortHouston$17.6M
- Isabella GlitzaHouston$14.8M
- Murtaza MussajiHouston$13.1M
- Hussein TawbiHouston$12.6M
- Hans LeeHouston$11.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.